Investors Sue Fertility Treatment Co. Following FDA Letter
Law360, New York (September 16, 2013, 6:00 PM EDT) -- OvaScience Inc. and its top brass were hit with a putative shareholder class action Monday following a company announcement that it was suspending trials of its flagship fertility treatment because of drug classification concerns by the U.S. Food and Drug Administration.
Cambridge, Mass.-based OvaScience was sued in Massachusetts federal court by Meriam Ratner, an investor who claimed the life sciences company misrepresented that its fertility treatment Augment would not need FDA approval to be tested or marketed. The FDA announced on Sept. 10 that the treatment would need approval, causing OvaScience stock to drop 23 percent, according to the suit. ...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!